Tenaya Therapeutics, Inc. [Rocket]

In millions, except per share items	Dec-31-22	Dec-05-22	Dec-31-21	Dec-05-21	Dec-31-20	Dec-31-19
	10-K	8-K	10-K	8-K	10-K	S-1
Revenues	0.0	94.5	0.0	54.4	0.0	23.1
Revenue growth		73.8%			-100.0%
Cost of goods sold	0.0	125.6	0.0	72.8	0.0	27.7
Gross profit	0.0	-31.1	0.0	-18.4	0.0	-4.6
Gross margin		-32.9%		-33.9%		-19.7%
Selling, general and administrative [+]	31.1	31.1	18.4	18.4	7.8	4.6
General and administrative	31.1	31.1	18.4	18.4	7.8	4.6
Research and development	94.5		54.4		31.1
Other operating expenses		63.5		36.0		18.6
EBITDA [+]	-119.2		-69.8		-36.4	-25.7
EBITDA growth	70.6%	72.5%	91.7%		41.6%
EBITDA margin		-132.9%		-133.9%		-111.1%
Depreciation and amortization	6.5		3.0		2.5	2.0
EBIT [+]	-125.6	-125.6	-72.8	-72.8	-38.9	-27.7
EBIT growth	72.5%	72.5%	87.1%		40.4%
EBIT margin		-132.9%		-133.9%		-119.7%
Interest income	2.0		0.1		0.1	0.5
Interest income	2.0		0.1		0.1	0.5
Other income (expense), net [+]	0.0	2.0	0.0	0.1	0.4	1.0
Other	0.0	0.0	0.0	0.0	0.4	1.0
Pre-tax income	-123.7	-123.7	-72.7	-72.7	-38.4	-26.2
Income taxes	0.0	0.0	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net income	-123.7	-123.7	-72.7	-72.7	-38.4	-26.2
Net margin		-130.8%		-133.7%		-113.3%

Basic EPS [+]	($2.76)	($2.76)	($4.10)	($4.10)	($39.50)	($5.78)
Growth	-32.7%	-32.7%	-89.6%		582.9%
Diluted EPS [+]	($2.76)	($2.76)	($4.10)	($4.10)	($39.50)	($5.78)
Growth	-32.7%	-32.7%	-89.6%		582.9%

Shares outstanding (basic) [+]	44.8	44.8	17.7	17.7	1.0	4.5
Growth	152.8%	152.8%	1724.3%		-78.6%
Shares outstanding (diluted) [+]	44.8	44.8	17.7	17.7	1.0	4.5
Growth	152.8%	152.8%	1724.3%		-78.6%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.